 | • レポートコード：GIR-107A12515 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、125ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、アンジオテンシンII受容体拮抗薬用非ペプチド薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。アンジオテンシンII受容体拮抗薬用非ペプチド薬の種類別市場規模（バルサルタン、イルベサルタン、カンデサルタンシレクセチル、エプロサルタン、イルベサルタン、テルミサルタン、ロサルタン、オルメサルタンメドキソミル、アリサルタンイソプロキシル）、用途別市場規模（高血圧、うっ血性心不全、左心室肥大、アテローム性動脈硬化症、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・アンジオテンシンII受容体拮抗薬用非ペプチド薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Pfizer、Novartis、Merck、AstraZeneca、Jhonson and Johnson、Eli Lilly、Sanofi、Bristol-Myers Squibb、Bayer、GSK、Teva Pharmaceutical、Shenzhen Salubris Pharmaceuticals 、Sun Pharmaceutical、Mylan、Alembic Pharmaceuticals、Lupin、Aurobindo Pharma、Amneal Pharmaceuticals、Boehringer Ingelheim ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：バルサルタン、イルベサルタン、カンデサルタンシレクセチル、エプロサルタン、イルベサルタン、テルミサルタン、ロサルタン、オルメサルタンメドキソミル、アリサルタンイソプロキシル ・用途別分析2016年-2026年：高血圧、うっ血性心不全、左心室肥大、アテローム性動脈硬化症、その他 ・アンジオテンシンII受容体拮抗薬用非ペプチド薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・アンジオテンシンII受容体拮抗薬用非ペプチド薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・アンジオテンシンII受容体拮抗薬用非ペプチド薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・アンジオテンシンII受容体拮抗薬用非ペプチド薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・アンジオテンシンII受容体拮抗薬用非ペプチド薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Non-Peptide Drugs of Angiotensin II Receptor Antagonist market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Non-Peptide Drugs of Angiotensin II Receptor Antagonist size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Non-Peptide Drugs of Angiotensin II Receptor Antagonist market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Non-Peptide Drugs of Angiotensin II Receptor Antagonist market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Valsartan
Irbesartan
Candesartan Cilexetil
Eprosartan
Irbesartan
Telmisartan
losartan
Olmesartan Medoxomil
Allisartan isoproxil
Market segment by Application, can be divided into
High Blood Pressure
Congestive Heart Failure
Left Ventricular Hypertrophy
Atherosclerosis
Other
Market segment by players, this report covers
Pfizer
Novartis
Merck
AstraZeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Shenzhen Salubris Pharmaceuticals
Sun Pharmaceutical
Mylan
Alembic Pharmaceuticals
Lupin
Aurobindo Pharma
Amneal Pharmaceuticals
Boehringer Ingelheim
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Non-Peptide Drugs of Angiotensin II Receptor Antagonist
1.2 Classification of Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Type
1.2.1 Overview: Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Type in 2020
1.2.3 Valsartan
1.2.4 Irbesartan
1.2.5 Candesartan Cilexetil
1.2.6 Eprosartan
1.2.7 Irbesartan
1.2.8 Telmisartan
1.2.9 losartan
1.2.10 Olmesartan Medoxomil
1.2.11 Allisartan isoproxil
1.3 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market by Application
1.3.1 Overview: Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 High Blood Pressure
1.3.3 Congestive Heart Failure
1.3.4 Left Ventricular Hypertrophy
1.3.5 Atherosclerosis
1.3.6 Other
1.4 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size & Forecast
1.5 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast by Region
1.5.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region, (2016-2021)
1.5.3 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Prospect (2016-2026)
1.5.4 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Prospect (2016-2026)
1.5.6 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Drivers
1.6.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Restraints
1.6.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Trends Analysis
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.1.4 Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.2.4 Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Merck
2.3.1 Merck Details
2.3.2 Merck Major Business
2.3.3 Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.3.4 Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Merck Recent Developments and Future Plans
2.4 AstraZeneca
2.4.1 AstraZeneca Details
2.4.2 AstraZeneca Major Business
2.4.3 AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.4.4 AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 AstraZeneca Recent Developments and Future Plans
2.5 Jhonson and Johnson
2.5.1 Jhonson and Johnson Details
2.5.2 Jhonson and Johnson Major Business
2.5.3 Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.5.4 Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Jhonson and Johnson Recent Developments and Future Plans
2.6 Eli Lilly
2.6.1 Eli Lilly Details
2.6.2 Eli Lilly Major Business
2.6.3 Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.6.4 Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Eli Lilly Recent Developments and Future Plans
2.7 Sanofi
2.7.1 Sanofi Details
2.7.2 Sanofi Major Business
2.7.3 Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.7.4 Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Sanofi Recent Developments and Future Plans
2.8 Bristol-Myers Squibb
2.8.1 Bristol-Myers Squibb Details
2.8.2 Bristol-Myers Squibb Major Business
2.8.3 Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.8.4 Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.9 Bayer
2.9.1 Bayer Details
2.9.2 Bayer Major Business
2.9.3 Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.9.4 Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Bayer Recent Developments and Future Plans
2.10 GSK
2.10.1 GSK Details
2.10.2 GSK Major Business
2.10.3 GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.10.4 GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 GSK Recent Developments and Future Plans
2.11 Teva Pharmaceutical
2.11.1 Teva Pharmaceutical Details
2.11.2 Teva Pharmaceutical Major Business
2.11.3 Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.11.4 Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Teva Pharmaceutical Recent Developments and Future Plans
2.12 Shenzhen Salubris Pharmaceuticals
2.12.1 Shenzhen Salubris Pharmaceuticals Details
2.12.2 Shenzhen Salubris Pharmaceuticals Major Business
2.12.3 Shenzhen Salubris Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.12.4 Shenzhen Salubris Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Shenzhen Salubris Pharmaceuticals Recent Developments and Future Plans
2.13 Sun Pharmaceutical
2.13.1 Sun Pharmaceutical Details
2.13.2 Sun Pharmaceutical Major Business
2.13.3 Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.13.4 Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Sun Pharmaceutical Recent Developments and Future Plans
2.14 Mylan
2.14.1 Mylan Details
2.14.2 Mylan Major Business
2.14.3 Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.14.4 Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Mylan Recent Developments and Future Plans
2.15 Alembic Pharmaceuticals
2.15.1 Alembic Pharmaceuticals Details
2.15.2 Alembic Pharmaceuticals Major Business
2.15.3 Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.15.4 Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Alembic Pharmaceuticals Recent Developments and Future Plans
2.16 Lupin
2.16.1 Lupin Details
2.16.2 Lupin Major Business
2.16.3 Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.16.4 Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Lupin Recent Developments and Future Plans
2.17 Aurobindo Pharma
2.17.1 Aurobindo Pharma Details
2.17.2 Aurobindo Pharma Major Business
2.17.3 Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.17.4 Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 Aurobindo Pharma Recent Developments and Future Plans
2.18 Amneal Pharmaceuticals
2.18.1 Amneal Pharmaceuticals Details
2.18.2 Amneal Pharmaceuticals Major Business
2.18.3 Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.18.4 Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.18.5 Amneal Pharmaceuticals Recent Developments and Future Plans
2.19 Boehringer Ingelheim
2.19.1 Boehringer Ingelheim Details
2.19.2 Boehringer Ingelheim Major Business
2.19.3 Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
2.19.4 Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, Gross Margin and Market Share (2019-2021)
2.19.5 Boehringer Ingelheim Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players Market Share
3.2.2 Top 10 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players Market Share
3.2.3 Market Competition Trend
3.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Market Share by Type (2016-2021)
4.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Application (2016-2021)
5.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Type (2016-2026)
6.2 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Application (2016-2026)
6.3 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country
6.3.1 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Country (2016-2026)
6.3.2 United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
6.3.3 Canada Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
6.3.4 Mexico Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Type (2016-2026)
7.2 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Application (2016-2026)
7.3 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country
7.3.1 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Country (2016-2026)
7.3.2 Germany Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
7.3.3 France Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
7.3.5 Russia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
7.3.6 Italy Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Type (2016-2026)
8.2 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Application (2016-2026)
8.3 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Region
8.3.1 Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Region (2016-2026)
8.3.2 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
8.3.3 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
8.3.4 South Korea Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
8.3.5 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
8.3.7 Australia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Type (2016-2026)
9.2 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Application (2016-2026)
9.3 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country
9.3.1 South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Country (2016-2026)
9.3.2 Brazil Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
9.3.3 Argentina Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Type (2016-2026)
10.2 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Application (2016-2026)
10.3 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Country
10.3.1 Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Country (2016-2026)
10.3.2 Turkey Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
10.3.4 UAE Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million) by Region (2016-2021)
Table 5. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Region (2021-2026)
Table 6. Pfizer Corporate Information, Head Office, and Major Competitors
Table 7. Pfizer Major Business
Table 8. Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 9. Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Novartis Corporate Information, Head Office, and Major Competitors
Table 11. Novartis Major Business
Table 12. Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 13. Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Merck Corporate Information, Head Office, and Major Competitors
Table 15. Merck Major Business
Table 16. Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 17. Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 19. AstraZeneca Major Business
Table 20. AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 21. AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Jhonson and Johnson Corporate Information, Head Office, and Major Competitors
Table 23. Jhonson and Johnson Major Business
Table 24. Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 25. Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 27. Eli Lilly Major Business
Table 28. Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 29. Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Sanofi Corporate Information, Head Office, and Major Competitors
Table 31. Sanofi Major Business
Table 32. Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 33. Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 35. Bristol-Myers Squibb Major Business
Table 36. Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 37. Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Bayer Corporate Information, Head Office, and Major Competitors
Table 39. Bayer Major Business
Table 40. Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 41. Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. GSK Corporate Information, Head Office, and Major Competitors
Table 43. GSK Major Business
Table 44. GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 45. GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Teva Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 47. Teva Pharmaceutical Major Business
Table 48. Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 49. Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Shenzhen Salubris Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 51. Shenzhen Salubris Pharmaceuticals Major Business
Table 52. Shenzhen Salubris Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 53. Shenzhen Salubris Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Sun Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 55. Sun Pharmaceutical Major Business
Table 56. Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 57. Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Mylan Corporate Information, Head Office, and Major Competitors
Table 59. Mylan Major Business
Table 60. Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 61. Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Alembic Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 63. Alembic Pharmaceuticals Major Business
Table 64. Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 65. Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Lupin Corporate Information, Head Office, and Major Competitors
Table 67. Lupin Major Business
Table 68. Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 69. Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Aurobindo Pharma Corporate Information, Head Office, and Major Competitors
Table 71. Aurobindo Pharma Major Business
Table 72. Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 73. Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. Amneal Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 75. Amneal Pharmaceuticals Major Business
Table 76. Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 77. Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 78. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors
Table 79. Boehringer Ingelheim Major Business
Table 80. Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product and Solutions
Table 81. Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 82. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million) by Players (2019-2021)
Table 83. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Players (2019-2021)
Table 84. Breakdown of Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Company Type (Tier 1, Tier 2 and Tier 3)
Table 85. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players Head Office, Products and Services Provided
Table 86. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Mergers & Acquisitions in the Past Five Years
Table 87. Non-Peptide Drugs of Angiotensin II Receptor Antagonist New Entrants and Expansion Plans
Table 88. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million) by Type (2016-2021)
Table 89. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Type (2016-2021)
Table 90. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Forecast by Type (2021-2026)
Table 91. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Application (2016-2021)
Table 92. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Forecast by Application (2021-2026)
Table 93. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Type (2016-2021) & (USD Million)
Table 94. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Type (2021-2026) & (USD Million)
Table 95. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Application (2016-2021) & (USD Million)
Table 96. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Application (2021-2026) & (USD Million)
Table 97. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Country (2016-2021) & (USD Million)
Table 98. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Country (2021-2026) & (USD Million)
Table 99. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Type (2016-2021) & (USD Million)
Table 100. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Type (2021-2026) & (USD Million)
Table 101. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Application (2016-2021) & (USD Million)
Table 102. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Application (2021-2026) & (USD Million)
Table 103. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Country (2016-2021) & (USD Million)
Table 104. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Country (2021-2026) & (USD Million)
Table 105. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Type (2016-2021) & (USD Million)
Table 106. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Type (2021-2026) & (USD Million)
Table 107. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Application (2016-2021) & (USD Million)
Table 108. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Application (2021-2026) & (USD Million)
Table 109. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Region (2016-2021) & (USD Million)
Table 110. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Region (2021-2026) & (USD Million)
Table 111. South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Type (2016-2021) & (USD Million)
Table 112. South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Type (2021-2026) & (USD Million)
Table 113. South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Application (2016-2021) & (USD Million)
Table 114. South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Application (2021-2026) & (USD Million)
Table 115. South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Country (2016-2021) & (USD Million)
Table 116. South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Country (2021-2026) & (USD Million)
Table 117. Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Type (2016-2021) & (USD Million)
Table 118. Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Type (2021-2026) & (USD Million)
Table 119. Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Application (2016-2021) & (USD Million)
Table 120. Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Application (2021-2026) & (USD Million)
Table 121. Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Country (2016-2021) & (USD Million)
Table 122. Middle East & Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Picture
Figure 2. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Type in 2020
Figure 3. Valsartan
Figure 4. Irbesartan
Figure 5. Candesartan Cilexetil
Figure 6. Eprosartan
Figure 7. Irbesartan
Figure 8. Telmisartan
Figure 9. losartan
Figure 10. Olmesartan Medoxomil
Figure 11. Allisartan isoproxil
Figure 12. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Application in 2020
Figure 13. High Blood Pressure Picture
Figure 14. Congestive Heart Failure Picture
Figure 15. Left Ventricular Hypertrophy Picture
Figure 16. Atherosclerosis Picture
Figure 17. Other Picture
Figure 18. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 19. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Forecast (2016-2026) & (USD Million)
Figure 20. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Region (2016-2026)
Figure 21. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Region in 2020
Figure 22. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million) and Growth Rate (2016-2026)
Figure 24. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million) and Growth Rate (2016-2026)
Figure 25. South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million) and Growth Rate (2016-2026)
Figure 26. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (USD Million) and Growth Rate (2016-2026)
Figure 27. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Drivers
Figure 28. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Restraints
Figure 29. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Trends
Figure 30. Pfizer Recent Developments and Future Plans
Figure 31. Novartis Recent Developments and Future Plans
Figure 32. Merck Recent Developments and Future Plans
Figure 33. AstraZeneca Recent Developments and Future Plans
Figure 34. Jhonson and Johnson Recent Developments and Future Plans
Figure 35. Eli Lilly Recent Developments and Future Plans
Figure 36. Sanofi Recent Developments and Future Plans
Figure 37. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 38. Bayer Recent Developments and Future Plans
Figure 39. GSK Recent Developments and Future Plans
Figure 40. Teva Pharmaceutical Recent Developments and Future Plans
Figure 41. Shenzhen Salubris Pharmaceuticals Recent Developments and Future Plans
Figure 42. Sun Pharmaceutical Recent Developments and Future Plans
Figure 43. Mylan Recent Developments and Future Plans
Figure 44. Alembic Pharmaceuticals Recent Developments and Future Plans
Figure 45. Lupin Recent Developments and Future Plans
Figure 46. Aurobindo Pharma Recent Developments and Future Plans
Figure 47. Amneal Pharmaceuticals Recent Developments and Future Plans
Figure 48. Boehringer Ingelheim Recent Developments and Future Plans
Figure 49. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Players in 2020
Figure 50. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 51. Global Top 3 Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share in 2020
Figure 52. Global Top 10 Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share in 2020
Figure 53. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 54. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Type in 2020
Figure 55. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share Forecast by Type (2021-2026)
Figure 56. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Share by Application in 2020
Figure 57. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share Forecast by Application (2021-2026)
Figure 58. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Type (2016-2026)
Figure 59. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Application (2016-2026)
Figure 60. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Country (2016-2026)
Figure 61. United States Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Canada Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Mexico Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Type (2016-2026)
Figure 65. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Application (2016-2026)
Figure 66. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Country (2016-2026)
Figure 67. Germany Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. France Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. United Kingdom Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Russia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Italy Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Type (2016-2026)
Figure 73. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Application (2016-2026)
Figure 74. Asia-Pacific Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Region (2016-2026)
Figure 75. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. South Korea Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Australia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Type (2016-2026)
Figure 82. South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Application (2016-2026)
Figure 83. South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Country (2016-2026)
Figure 84. Brazil Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 85. Argentina Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 86. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Type (2016-2026)
Figure 87. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Sales Market Share by Application (2016-2026)
Figure 88. Middle East and Africa Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Country (2016-2026)
Figure 89. Turkey Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 90. Saudi Arabia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 91. UAE Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 92. Methodology
Figure 93. Research Process and Data Source
世界のN-ホルミルペプチド受容体2市場 2021：企業別、地域別、種類・用途別 The N-Formyl Peptide Receptor 2 market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade reg…- 世界のアンジオテンシンII受容体市場 2021：企業別、地域別、種類・用途別 The Angiotensin II Receptor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…
- 世界のグルカゴン様ペプチド2受容体市場 2021：企業別、地域別、種類・用途別 The Glucagon Like Peptide 2 Receptor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trad…
- 世界のカルシトニン遺伝子関連ペプチド1型受容体市場 2021：企業別、地域別、種類・用途別 The Calcitonin Gene Related Peptide Type 1 Receptor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain opt…
- 世界の高血圧薬市場予測（～2024年）：メーカー別、地域別、種類・用途別 Antihypertensive drug is a kind of medicine that can control blood pressure and is used to treat hypertension. Scope of the Report: The worldwide market for Antihypertensive Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx millio…